Virginia SB 1135: Psilocybin Trigger Bill Explained

What Virginia SB 1135 does

Virginia SB 1135 is a conditional law that would activate a state psilocybin therapy program only after two specific federal events occur. The bill directs the Virginia Board of Pharmacy to write regulations for prescribing and dispensing psilocybin — but those regulations stay dormant until federal law changes first.

The bill was introduced in the 2025 legislative session by Senator Jennifer Boysko (D-Fairfax). It passed the full Senate by a vote of 40–0 and passed the House of Delegates 51–45. Governor Glenn Youngkin then vetoed it on March 24, 2025.

The bill is formally titled "Crystalline polymorph psilocybin; regulations for prescribing, dispensing, and use." The unusual phrase "crystalline polymorph" is not standard pharmacology language — it refers to a patented synthetic form of psilocybin developed by Compass Pathways.

Why a trigger bill?

A trigger bill lets a legislature signal support for a policy without directly defying current federal law. Because psilocybin is still a Schedule I drug under federal law, Virginia cannot simply legalize it outright without conflict. A trigger mechanism sidesteps that conflict: the state law only activates once federal law has already changed.

This also means no new legislative session is needed once the federal trigger fires. The program activates automatically. Legislators see this as getting ahead of the curve on an issue that may move quickly.

The exact trigger conditions

Virginia SB 1135 requires two separate federal actions before the Board of Pharmacy can implement its regulations. Both must occur; one alone is not enough.

The two conditions are:

1. FDA approval: The U.S. Food and Drug Administration must approve a pharmaceutical product containing crystalline polymorph psilocybin. This means a company must have completed clinical trials and received an approved New Drug Application (NDA).
2. DEA rescheduling: The U.S. Drug Enforcement Administration must reschedule psilocybin at the federal level — meaning move it out of Schedule I. FDA approval of a drug typically triggers an automatic DEA rescheduling review, but the bill requires the rescheduling to actually happen, not just be under review.

The specific language — "crystalline polymorph psilocybin" — matters here. If the FDA approved a different form of synthetic psilocybin that does not match the crystalline polymorph patent profile, it is unclear whether the original bill text would have been triggered. A committee substitute broadened the language in the 2025 session to cover any FDA-approved, DEA-rescheduled psilocybin product, not just the patented form.

What the program would look like

If triggered, Virginia SB 1135 would create a standard prescription drug program — not a supervised experience model like Oregon or Colorado's healing centers.

Under SB 1135's framework, a licensed healthcare provider in Virginia with prescribing authority could write a prescription for an FDA-approved psilocybin product. A licensed pharmacist could then fill and dispense it. The patient takes the medication under whatever clinical guidance the prescriber sets, not at a licensed facility with a trained facilitator.

The Board of Pharmacy would write the specific rules: dosing limits, dispensing records, patient eligibility requirements, and provider qualifications. The bill does not specify which medical conditions qualify. That detail would fall to the Board's rulemaking process after activation.

Who could prescribe and who could receive it

Any healthcare provider licensed to prescribe medications in Virginia and acting within their authorized scope of practice could prescribe a triggered psilocybin product. That includes physicians, nurse practitioners, and physician assistants with prescriptive authority, depending on how the Board of Pharmacy writes the rules.

There is no diagnosis requirement in the bill text itself. The program does not restrict psilocybin to treatment-resistant depression or any other specific indication. Clinical guidelines would likely mirror the FDA-approved indication — but prescribers could use off-label discretion just as with any other Schedule II or Schedule III medication.

This is a key operational detail that most comparisons miss: Virginia's model would give individual prescribers far more discretion than Oregon's or Colorado's facilitated-session programs, where the setting, dose, and supervision requirements are tightly regulated by state rule.

The COMP360 connection

The phrase "crystalline polymorph psilocybin" in SB 1135 is not a pharmacological term in wide scientific use — it describes a specific chemical form of psilocybin patented by the UK company Compass Pathways, whose lead product is called COMP360.

Compass Pathways lobbied in favor of both Virginia SB 1135 and Colorado HB 25-1063. Critics argued that writing "crystalline polymorph psilocybin" into law would effectively give Compass a government-backed monopoly on psilocybin therapy in Virginia if COMP360 is the first or only product to receive FDA approval in that form. No other psilocybin product currently uses the crystalline polymorph patent profile.

The Virginia committee substitute addressed this concern by changing the trigger language to cover any FDA-approved psilocybin product that receives DEA rescheduling — not exclusively the crystalline polymorph form. That broader language is what passed the full Senate and House.

The veto and what comes next

Governor Glenn Youngkin vetoed SB 1135 on March 24, 2025. His veto statement called the legislation "premature" and argued that Virginia should not write regulations for a drug that the FDA has not yet approved.

Youngkin's exact words: "This legislation is premature to the appropriate FDA approval and DEA drug scheduling. No other drugs are anachronistically codified by the state before federal approval." The Senate voted to sustain the veto on April 2, 2025. No veto override succeeded.

The bill remains dead for the 2025 session. Virginia's governor's term runs through 2026. A new administration in 2026 could shift the political math significantly. Senator Boysko and other supporters have signaled intent to reintroduce the legislation in a future session.

Where Virginia stands today

Virginia has no legal pathway for psilocybin therapy. Possession, use, and distribution remain criminal offenses under state law and federal law. For a real-time picture of where each state stands, see the psychedelic legalization tracker.

Virginia does allow ketamine infusions through licensed clinics, as ketamine is FDA-approved and is not a Schedule I substance. If you are looking for legal psychedelic-assisted therapy in the U.S., see our guide to where psilocybin is legal and the legal status by state tool.

Virginia vs. other trigger bills

Virginia SB 1135 is one of several state trigger bills introduced in the 2025 legislative cycle that tie psilocybin access to FDA approval and DEA rescheduling. The table compares the four most-discussed.

What Virginia's model would have done differently from Rhode Island: Rhode Island's HB 5186 included a provision allowing personal home cultivation of psilocybin mushrooms, contingent on FDA action. Virginia's bill contained no such provision — it was a purely pharmaceutical, clinician-mediated model. When Colorado fits as a comparison: Colorado's HB 25-1063 is the closest analog to Virginia's SB 1135 in structure, and it is now law. See the full trigger bills guide for a deeper breakdown.

Federal law and what still blocks it

Psilocybin remains a Schedule I controlled substance under the federal Controlled Substances Act, meaning it has no accepted medical use and a high potential for abuse in the eyes of federal law. That Schedule I status is what both triggers in SB 1135 are designed to wait for.

FDA approval alone does not remove a substance from Schedule I automatically. The FDA-DEA process works like this: the FDA approves the drug, then refers the matter to the DEA, which has 90 days to initiate rescheduling. But the DEA can take longer, and the outcome is not guaranteed. Advocates worry that DEA rescheduling could take years after FDA approval, leaving trigger laws in limbo.

The FDA granted COMP360 Breakthrough Therapy designation for treatment-resistant depression — which speeds the review process but does not guarantee approval. Compass Pathways has been running Phase 3 trials. No FDA approval date has been announced as of mid-2026. For context on the FDA's role in psychedelic research, see the FDA breakthrough therapy explainer.

Even after a federal trigger, Virginia's Board of Pharmacy would need time to write and adopt regulations before anyone could legally prescribe or dispense. The Board's rulemaking process typically takes 12 to 18 months. That lag period is the hidden timing risk in any trigger bill — the law activates, but access does not begin immediately.

For context on the federal scheduling system that governs all of this, see the Controlled Substances Act guide. For where other states stand, see what psychedelics are legal in the US.